REGENXBIO Faces Class Action Lawsuit Over RGX-111

REGENXBIO Inc. is facing a class action securities lawsuit filed by Levi & Korsinsky, LLP. The lawsuit alleges that REGENXBIO made false and misleading statements regarding its investigational gene therapy, RGX-111, for Hurler syndrome. Specifically, the complaint claims REGENXBIO provided overly positive assertions about RGX-111's trial success, while concealing material adverse facts about its efficacy and safety. This came to light after the United States===Food and Drug Administration placed a clinical hold on RGX-111 due to the discovery of an intraventricular CNS tumor in a study participant. Following this announcement, REGENXBIO's stock price dropped by 17.8% in one day. Investors who suffered losses between February 9, 2022, and January 27, 2026, have until April 14, 2026, to request to be appointed as lead plaintiff.